VivoSeq
Other

Newborns

0

Pipeline Programs

0

Active Trials

0

Companies Involved

Newborns is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

13/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Completed12 · 75%
Unknown status2 · 13%
Terminated1 · 6%
Withdrawn1 · 6%

Trial Activity

16 trials

Intraoral 30% Glucose Effect In Newborns
Completed··Phase 3·NCT02325583·19 enrolled
Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns
Completed··Phase 2·NCT01605279·127 enrolled
Supplementation With Lactoferrin in Preterm Newborns
Completed·UUniversity of Siena·Phase 4·NCT01172236·1,300 enrolled
Pharmacokinetics of Oseltamivir in Newborns and Infants
Completed··N/A·NCT01388439·19 enrolled
Early Versus Late Caffeine for ELBW Newborns
Terminated·WWayne State University·N/A·NCT02524249·110 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)